Good AI Capital

What Good AI Capital does

Good AI Capital is a Menlo Park-based venture capital firm founded in 2017 and operating as Good AI Capital GP, LLC. The firm invests in AI-focused startups from pre-seed through IPO across three stated verticals — Healthcare, Enterprise, and Automation — backing what it describes as 'technical visionaries' applying AI to healthcare, enterprise software, synthetic biology, drug delivery, robotics, and autonomous systems. Its disclosed portfolio spans synthetic biology and ML-driven materials (Aether, bit.bio, Pragma Bio, Mekonos), autonomous delivery robotics (Serve Robotics), fintech (Uplift, SoFi), and other AI ventures, with notable outcomes including Uplift's $100M acquisition by Upgrade, SoFi's $13B SPAC merger, and Serve Robotics' public offering.

The firm's go-to-market is direct equity investment sourced through a curated LP/advisory network that includes Eric S. Yuan (Zoom), Tim Draper (Draper Ventures), and Gokul Rajaram, alongside industry partnerships with accelerators, co-investors, research institutions (including Stanford's Canary Center), and an industry network. The firm differentiates on a mission-driven 'doing well by doing good' thesis, a stated focus on the intersection of technology and biology, and a founder-centric support model that supplies strategic and operational assistance plus talent and customer access. Its internal team is small — Founder/General Partner Darwin Ling, Venture Partner Daniel Kwan MD, and Principal Charles Wang — and it uses a Substack blog as its primary thought-leadership channel. Pricing and fund terms are not publicly disclosed, consistent with private VC operations.

Name

Good AI Capital

Legal name

Good AI Capital GP, LLC

Website

https://goodai.capital

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Good AI Capital is a Menlo Park-based venture capital firm founded in 2017 that backs AI-focused startups across healthcare, enterprise, and automation, providing capital and operational support from pre-seed through IPO.

Ownership category

akta.pro rank

Product category

Venture Capital

NAICS

Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394), Other Investment Pools and Funds (5259), Funds, Trusts, and Other Financial Vehicles (525)

SIC

Investment Advice (6282)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

akta.pro secondary industries

Technology & Software Growth Equity (FSANACAA), Financial Services / Fintech Growth Equity (FSANACAE)

Keywords

• Venture capital investing
• AI startup funding
• Early-stage equity investments
• Healthcare AI investments
• Enterprise technology funding

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Distribution channels1 record

Marketing channels1 record

Core offering

Good AI Capital is a venture capital firm that invests equity capital in AI-focused startups from pre-seed through IPO, spanning Healthcare, Enterprise, and Automation sectors. In addition to capital, the firm provides strategic and operational support, talent introductions, customer access, and expert network resources to help portfolio companies scale. Notable portfolio companies include SoFi, Serve Robotics, bit.bio, Aether, Mekonos, Pragma Bio, and Uplift.

Product overview

Good AI Capital is a venture capital firm, not a product company. It does not offer products or services in the traditional sense. The company's offering consists of investment capital, strategic and operational support, and access to talent, customers, and an expert network to help AI-focused startups scale. Its portfolio spans Healthcare, Enterprise, and Automation sectors, including companies such as Aether (synthetic biology and machine learning), Serve Robotics (autonomous delivery robots), Mekonos (gene and cell therapy delivery), bit.bio (human cell programming), Pragma Bio, Uplift, SoFi, and other AI-focused ventures.

Differentiator

Problem solved

Functional benefit

Products and services

• Venture Capital Investment Equity capital investments in AI-focused startups from pre-seed through IPO across Healthcare, Enterprise, and Automation sectors, paired with strategic and operational support. Targeted at technical visionary founders building companies at the intersection of technology and biology.

Quantifiable outcome

• Portfolio includes companies with $100M acquisition, $13B IPO valuation, and multiple successful funding rounds

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered minor and core.

• AcceleratorsminorStrategic or Co-development PartnerIndustry partner category shown on website indicating partnerships with accelerator programs in the Good AI Capital ecosystem
• Research InstitutionsminorStrategic or Co-development PartnerResearch institution partners shown on website, including Stanford Canary Center represented by Prof. Utkan Demirci on the advisory board
• Industry NetworkminorOthersIndustry network partners shown on website including various technology and healthcare companies
• Ginkgo BioworkscoreStrategic or Co-development Partnerbit.bio, a portfolio company of Good AI Capital, was announced as inaugural partner of Ginkgo Bioworks' new Technology Network in February 2024
• Magna InternationalcoreStrategic or Co-development PartnerServe Robotics, a portfolio company of Good AI Capital, entered a production agreement with Magna to scale robot manufacturing in April 2024
• MJFF (Michael J. Fox Foundation)minorStrategic or Co-development Partnerbit.bio partnered with MJFF to develop human cell products for Parkinson's research, announced March 2024

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Lerer Hippeau: Early-stage NYC-based venture firm with AI and enterprise focus. Comparable as a smaller specialist fund backing technical founders, though more enterprise and consumer-tech oriented.
• DCVC (Data Collective): Deep tech and AI-focused venture firm investing in computational biology, automation, and enterprise AI. Highly comparable thesis to Good AI Capital, particularly around the AI-meets-biology intersection (bit.bio, Mekonos overlap).
• Khosla Ventures: Tech-focused venture firm with deep AI, healthcare, and sustainability exposure. Comparable to Good AI Capital in cross-sector AI investing and willingness to back technical visionaries at pre-seed through IPO.
• Obvious Ventures: Mission-driven venture firm explicitly built on a "doing well by doing good" thesis. Directly comparable to Good AI Capital's stated philosophy of combining positive impact with outsize returns across healthcare, enterprise, and automation.
• Lux Capital: Early-stage venture firm investing in AI, deep tech, and frontier science. Closely comparable to Good AI Capital in sector focus (AI + biology intersection), stage (seed through growth), and mission-driven thesis around transformative technologies.
• Zetta Venture Partners: Early-stage venture firm focused on AI-first companies building enterprise data and intelligence products. Smaller specialist fund comparable to Good AI Capital's size and sector focus.
• Bloomberg Beta: Early-stage venture firm focused on enterprise and applied AI. Comparable as a sector-focused specialist fund backing AI founders from pre-seed onward.
• Playground Global: Deep tech and AI venture firm investing in robotics, autonomy, and computational biology. Directly comparable sector overlap (autonomous systems like Serve Robotics, biotech like bit.bio).

Broad incumbents

• B Capital Group: Multi-stage technology venture firm with AI, healthcare, and enterprise focus. Broader portfolio and global reach than Good AI Capital but comparable sector thesis.
• Andreessen Horowitz (a16z): Large multi-stage venture firm with significant AI investing practice (a16z Bio, a16z infra). Comparable as a competitor for AI deals but operates at much greater scale and broader scope than Good AI Capital's focused thesis.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/goodaicapital

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments11 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Good AI Capital